Cargando…

Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer

Concurrent chemoradiotherapy (CRT) has been recommended and applied widely as the standard treatment for limited‐stage small cell lung cancer (LS‐SCLC). However, controversies remain regarding the optimal timing and treatment duration of thoracic radiotherapy (TRT), and their effects on patient surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Shen, Zhou, Ting, Ma, Shuxiang, Zhao, Yuanyuan, Zhan, Jianhua, Fang, Wenfeng, Yang, Yunpeng, Hou, Xue, Zhang, Zhonghan, Chen, Gang, Zhang, Yaxiong, Huang, Yan, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143999/ https://www.ncbi.nlm.nih.gov/pubmed/30019533 http://dx.doi.org/10.1002/cam4.1616

Ejemplares similares

Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study
por: Liu, Jiaqing, et al.
Publicado: (2019)

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)
por: Zhou, Ting, et al.
Publicado: (2017)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
por: Hou, Xue, et al.
Publicado: (2018)

Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells
por: Hou, Xue, et al.
Publicado: (2023)

Trends in incidence and associated risk factors of suicide mortality in patients with non‐small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2018)

A modifiable risk factors atlas of lung cancer: A Mendelian randomization study
por: Shen, Jiayi, et al.
Publicado: (2021)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

A large, single‐center, real‐world study of clinicopathological characteristics and treatment in advanced ALK‐positive non‐small‐cell lung cancer
por: Chen, Gang, et al.
Publicado: (2017)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Value of radiotherapy in addition to esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma: Analysis of surveillance, epidemiology, and end results database
por: Yu, Jing, et al.
Publicado: (2018)

Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model
por: Ren, Kang, et al.
Publicado: (2021)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Chen, Yu, et al.
Publicado: (2021)

Impact of prior cancer history on the overall survival of younger patients with lung cancer
por: Liu, Jiaqing, et al.
Publicado: (2020)

Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis
por: Zhang, Yaxiong, et al.
Publicado: (2016)

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited-stage small-cell lung cancer?
por: Wang, Peng, et al.
Publicado: (2015)

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2021)

Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer
por: Luo, Youli, et al.
Publicado: (2021)

What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?
por: Higgins, Kristin A., et al.
Publicado: (2020)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer
por: Verma, Saurav, et al.
Publicado: (2023)

Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes
por: Wang, Zhiwu, et al.
Publicado: (2020)

Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
por: Shen, Jiayi, et al.
Publicado: (2020)

A six-gene-based signature for breast cancer radiotherapy sensitivity estimation
por: Chen, Xing, et al.
Publicado: (2020)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
por: Lok, Benjamin H., et al.
Publicado: (2017)

The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2017)

Survival following radiotherapy in young women with localized early‐stage breast cancer according to molecular subtypes
por: Liu, Qi‐Qi, et al.
Publicado: (2019)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to up-regulate ZEB1 and MDM2
por: Zhang, Fenghua, et al.
Publicado: (2020)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing
por: Zhang, Yaxiong, et al.
Publicado: (2019)

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2019)

Occupational Diesel Exposure, Duration of Employment, and Lung Cancer: An Application of the Parametric G-Formula
por: Neophytou, Andreas M., et al.
Publicado: (2016)

Consolidative thoracic radiotherapy for extensive stage small cell lung cancer
por: Zhang, Xiaoli, et al.
Publicado: (2017)

Acetate promotes SNAI1 expression by ACSS2-mediated histone acetylation under glucose limitation in renal cell carcinoma cell
por: Yao, Lv, et al.
Publicado: (2020)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?
por: Barros, José Máximo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jbj3voc31c1fffe9t0dkkgluh3